This study suggested that NPC1 could be a valuable biomarker for identifying, predicting outcomes, and assessment of treatment response in HCC patients, offering new avenues for clinical management and therapeutic intervention. This evidence concerns the gene NPC1 and hepatocellular carcinoma.